• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Delayed denosumab doses associated with increased the risk of vertebral fractures

byHarsh ShahandDeepti Shroff Karhade
July 30, 2020
in Chronic Disease, Obstetrics, Surgery
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Delayed subsequent denosumab doses were shown to increase the risk for vertebral fractures compared to on-time injection.

2. There was insufficient evidence to determine if with delayed dosing, fracture risk at other locations would be increased.

Evidence Rating Level: 2 (Good)

Study Rundown: Denosumab, a monoclonal antibody that inhibits the RANK ligand on osteoblasts, is an effective treatment for osteoporosis. Discontinuation of the therapy results in accelerated bone turnover and rapid loss of bone mineral density. Furthermore, cessation of denosumab has been associated with an increased risk of vertebral and hip fractures. However, the effect of delayed subsequent denosumab doses on fractures risks is yet to be determined. As such, this study examined the effect of denosumab delay on fracture risk. The study concluded that delayed denosumab doses only increased the risk for vertebral fractures and not fractures at other anatomical sites.  This retrospective cohort study was limited by statistical power for composite fracture and several secondary end points. Therefore, the data was not sufficient to conclude the risk of fractures at other anatomical sites was caused by a delayed denosumab dosing regimen. Nonetheless, this study was strengthened by the adoption of a target trial emulation design, which aligned the results from the study with those from randomized control trials since a randomized control trial within this patient population would be considered unethical.

Click to read the study in Annals of Internal Medicine

Relevant Reading: Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension

RELATED REPORTS

Inflammatory bowel disease may be associated with increased risk of osteoporosis and osteopeia

#VisualAbstract: Infrequent Zoledronate over 10 years Prevents Frcatures in Early Postmenopausal Women

Denosumab may increase risk of major adverse cardiovascular events but reduce fracture risk in patients receiving dialysis

In-Depth [retrospective cohort]: This retrospective, cohort study enrolled 2594 patients through The Health Improvement Network (THIN) database in the United Kingdom. Participants were included if they met the criteria of 45 years or older with an initiated denosumab treatment to manage osteoporosis between 2010 and 2019. Participants that received only 1 denosumab injection or used other antiosteoporosis drugs were excluded from the study. The recommended date for a subsequent denosumab dose was set to 6 months after a prior dose. The administration of a subsequent dose within 4 weeks was classified as “on-time”, a dose administered between 4 and 16 weeks was considered “short delay”, and a dose given at 6 months was classified as “long delay”. The primary outcome was composite fractures, which included all types of fractures. The secondary outcomes were osteoporotic fractures, which included vertebral fractures, hip fractures, and nonvertebral fractures. Over the 6-month period, the cumulative risk for composite fractures for the 3 groups was 27.3 in 1000 for “on-time”, 32.2 in 1000 for “short delay”, and 42.4 in 1000 for “long delay”. The risk difference between “short delay” and “on-time” dosing was 4.8 in 1000 (hazard ratio, 1.03, 95% confidence interval [CI], 0.63 to 1.69) compared to the risk difference between “long delay” and “on-time” dosing, which was 15.0 in 1000 (hazard ratio, 1.44, 95% CI, 0.96 to 2.17, P=0.093). Specifically focusing on vertebral fractures, the cumulative risk was 2.2 in 1000 for “on-time”, 3.6 in 1000 for “short delay”, and 10.1 in 1000 for “long delay”. The risk difference between “short delay” and “on-time” dosing was 1.4 in 1000 (hazard ratio, 1.48, 95% CI, 0.58 to 3.79) compared to the risk difference between “long delay” and “on-time” dosing, which was 7.9 in 1000 (hazard ratio, 3.91, 95% CI 1.62 to 9.45, P=0.005). Taken together, delaying subsequent denosumab doses increased the risk for composite fractures, especially vertebral fractures.

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: denosumabfracture riskosteoporosisvertebral fracture
Previous Post

Effects of substituting Sugar-Sweetened beverages with Artificially Sweetened, and Unsweetened Beverages on BMI and sweet taste preference #TA

Next Post

Effects of substituting Sugar-Sweetened beverages with Artificially Sweetened, and Unsweetened Beverages on BMI and sweet taste preference #VA

RelatedReports

Elective colectomy associated with improved survival in ulcerative colitis
Chronic Disease

Inflammatory bowel disease may be associated with increased risk of osteoporosis and osteopeia

April 17, 2025
#VisualAbstract: Infrequent Zoledronate over 10 years Prevents Frcatures in Early Postmenopausal Women
StudyGraphics

#VisualAbstract: Infrequent Zoledronate over 10 years Prevents Frcatures in Early Postmenopausal Women

January 22, 2025
Combined immunotherapy may improve survival in metastatic pancreatic cancer
Chronic Disease

Denosumab may increase risk of major adverse cardiovascular events but reduce fracture risk in patients receiving dialysis

January 13, 2025
Combined immunotherapy may improve survival in metastatic pancreatic cancer
Nephrology

Denosumab increases risk of severe hypocalcemia in women with osteoporosis and chronic kidney disease

November 18, 2024
Next Post
Effects of substituting Sugar-Sweetened beverages with Artificially Sweetened, and Unsweetened Beverages on BMI and sweet taste preference #VA

Effects of substituting Sugar-Sweetened beverages with Artificially Sweetened, and Unsweetened Beverages on BMI and sweet taste preference #VA

SARS-CoV-2 detected on various surroundings of asymptomatic COVID-19 positive infant

Hematological and coagulation parameters may predict outcomes in COVID-19

Elagolix with add-back hormone therapy effective in reducing fibroid-associated menstrual bleeding

Myomectomy associated with better fibroid-related quality of life versus uterine-artery embolization

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Tirzepatide-associated improvements in cardiometabolic risk factors linked to degree of weight loss
  • Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
  • 2 Minute Medicine Rewind June 23, 2025
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.